Biofrontera Inc. (NASDAQ:BFRI) Short Interest Update

Biofrontera Inc. (NASDAQ:BFRI) was the recipient of a large drop in short interest in the month of February. As of February 27th, there was short interest totaling 150,744 shares, a drop of 65.5% from the February 12th total of 436,863 shares. Approximately 1.4% of the company’s shares are short sold. Based on an average daily volume of 184,747 shares, the short-interest ratio is currently 0.8 days. Based on an average daily volume of 184,747 shares, the short-interest ratio is currently 0.8 days. Approximately 1.4% of the company’s shares are short sold.

Institutional Investors Weigh In On Biofrontera

A number of hedge funds have recently added to or reduced their stakes in the business. Rosalind Advisors Inc. boosted its position in Biofrontera by 51.5% in the 2nd quarter. Rosalind Advisors Inc. now owns 976,448 shares of the company’s stock valued at $695,000 after buying an additional 332,055 shares during the period. AIGH Capital Management LLC raised its stake in shares of Biofrontera by 7.3% in the third quarter. AIGH Capital Management LLC now owns 1,046,050 shares of the company’s stock valued at $1,030,000 after acquiring an additional 71,525 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Biofrontera by 54.2% in the fourth quarter. Geode Capital Management LLC now owns 65,677 shares of the company’s stock valued at $37,000 after acquiring an additional 23,074 shares in the last quarter. 10.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Benchmark reissued a “buy” rating on shares of Biofrontera in a research report on Friday, November 14th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Biofrontera presently has a consensus rating of “Hold” and a consensus price target of $2.75.

Biofrontera Stock Up 1.7%

NASDAQ:BFRI traded up $0.01 on Thursday, reaching $0.86. 16,741 shares of the company’s stock were exchanged, compared to its average volume of 570,994. The firm has a market capitalization of $10.02 million, a price-to-earnings ratio of -0.53 and a beta of 0.61. Biofrontera has a 52-week low of $0.54 and a 52-week high of $1.19. The business has a fifty day moving average of $0.86 and a 200-day moving average of $0.88.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.